Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report

• Main Authors: Yoichi Nishii (Author), Kazuki Furuhashi (Author), Kentaro Ito (Author), Tadashi Sakaguchi (Author), Yuta Suzuki (Author), Kentaro Fujiwara (Author), Taro Yasuma (Author), Tetsu Kobayashi (Author), Corina N. D'Alessandro-Gabazza (Author), Esteban C. Gabazza (Author), Osamu Taguchi (Author), Osamu Hataji (Author)
• Formato: Libro
• Publicado: MDPI AG, 2022-07-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Thymic carcinoma is a rare malignant tumor with a poor prognosis. No standard treatment is currently available. The present case was a 64-year-old male smoker with no symptoms referred to our hospital because of abnormal chest radiological findings. The CT study showed a tumor between the anterior m...